Intensity Therapeutics Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing

Intensity Therapeutics (Nasdaq: INTS) has approved a 1-for-25 reverse stock split, effective February 18, 2026, with trading on a split-adjusted basis commencing February 19. The MOVE aims to boost the company's share price to meet Nasdaq's minimum bid requirement, ensuring continued listing on the Nasdaq Capital Market.

Shareholders greenlit the reverse split during a special meeting on October 22, 2025. Post-split, the outstanding shares will shrink to approximately 2.53 million, while the total authorized shares remain unchanged. Fractional shares will be settled in cash, and all options and warrants will be adjusted proportionally.

The reverse split underscores Intensity Therapeutics' commitment to maintaining its Nasdaq listing as it advances its clinical programs. The company's stock recently traded around $0.2706, with the split designed to elevate the per-share price. The CUSIP identifier will change, but the INTS ticker symbol stays intact.